

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX SEQUENCE, Assistant Commissioner for Patents, Washington, D.C. 20231,

on March 5, 2001.

By:

Lois E. Miller
Lois E. Miller



PATENT 1643

Atty. Docket No. Box-SEL
DX0804K WBD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Christi L. PARHAM, et al.

Serial No.: 09/265,540

Filed: March 8, 1999

For: HUMAN RECEPTOR PROTEINS;
RELATED REAGENTS AND METHODS

Examiner: ~~C. S. S. S.~~
Hamud

Art Unit: ~~1643~~
1647

COMPUTER READABLE SEQUENCE
SUBMISSION

Palo Alto, California 94304

March 5, 2001

RECEIVED
MAR 09 2001
TECH CENTER 1600/2900

RECEIVED

MAR 15 2001

TECH CENTER 1600/2900

5 BOX Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

10 COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

15 In reply to receipt of a "Notice to Comply" with requirements for patent
applications containing nucleotide sequence and/or amino acid sequence
disclosures dated February 9, 2001, (paper no.15), for the above-identified
application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit:
(1) a write-protected diskette containing a computer-readable submission for the
"Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the
20 diskette.

REMARKS

25 Enclosed is a write protected floppy diskette with the sequence listing
generated by the Patent Office's PATENTIN 2.0 program. The Diskette should
comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a
PC-DOS/MS-DOS operating system. If the diskette has been damaged, please

call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.

I hereby state the informational contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.


Applicants have invested over seven hours of significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Date: March 5, 2001

By:



Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

enclosures and attachments:
one write-protected diskette (CRM)
paper copy of contents of diskette

DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
Main: (650) 852-9196
Direct: (650) 496-1244
Fax: (650) 496-1200